Race Oncology (ASX:RAC) has secured Human Research Ethics Committee approvals from the Institutional Review Board of The University of Hong Kong to commence its Phase 1 clinical trial of RC220 in combination with doxorubicin (RAC-010) at the Prince of Wales and Queen Mary Hospitals.
It stated that formal Department of Health approval has been received for the Queen Mary Hospital and is expected for the Prince of Wales Hospital in the coming weeks. Site activations are scheduled to follow from late July to mid-August, enabling patient recruitment to commence.
The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics of RC220 alone and in combination with doxorubicin, in patients with solid tumours.
Dr Herbert Loong, Principal Investigator at Prince of Wales Hospital, said, “Cancer patients being treated with cardiotoxic agents need the potential cardiac protection and added efficacy that RC220 may bring. We are extremely excited to be recruiting patients to this important trial.”
Dr Roland Ching-Yu Leung, Principal Investigator at Queen Mary Hospital, said, “This trial is a declaration that cardio-oncology cannot be overlooked. RC220 may be the agent that protects the heart against doxorubicin damage and adds efficacy. We are very excited.”
Race Vice President of Medical, Dr Simon Fisher, added, “We are delighted to have received human ethics approval for our RC220 Phase 1 trial in Hong Kong with the support of two internationally recognised clinical investigators. I wish to thank both Dr Loong and Dr Leung for their support and enthusiasm in progressing RC220 and I look forward to our respective teams working together in the coming months.”